Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A-mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A-mutant cancer cell...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Kwan, Suet-Yan, Cheng, Xuanjin, Tsang, Yvonne T.M., Choi, Jong-Sun, Kwan, Suet-Ying, Izaguirre, Daisy I., Kwan, Hoi-Shan, Gershenson, David M., Wong, Kwong-Kwok
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2016
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5302963/
https://ncbi.nlm.nih.gov/pubmed/27486766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10921
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk